{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:35:36Z","timestamp":1792888536469,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00210-026-05739-2","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:41:14Z","timestamp":1784691674000},"page":"21355-21371","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tacrolimus combined with everolimus versus sirolimus in organ transplantation: a comparative pharmacovigilance analysis of the FDA Adverse Event Reporting System"],"prefix":"10.1007","volume":"399","author":[{"given":"Yanlang","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangyan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haolin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"issue":"1","key":"5739_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/TP.0b013e3181aa7d87","volume":"88","author":"L Albano","year":"2009","unstructured":"Albano L, Berthoux F, Moal MC et al (2009) Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus. Transplantation 88(1):69\u201376","journal-title":"Transplantation"},{"issue":"15","key":"5739_CR2","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1001\/jama.2025.14338","volume":"334","author":"CS Almond","year":"2025","unstructured":"Almond CS, Daly KP, Albers EL et al (2025) Teammate trial investigators. Everolimus and low-dose tacrolimus after heart transplant in children: a randomized clinical trial. JAMA 334(15):1339\u20131348","journal-title":"JAMA"},{"issue":"6","key":"5739_CR3","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1159\/000495081","volume":"48","author":"AA Awan","year":"2018","unstructured":"Awan AA, Niu J, Pan JS et al (2018) Trends in the causes of death among kidney transplant recipients in the United States (1996\u20132014). Am J Nephrol 48(6):472\u2013481","journal-title":"Am J Nephrol"},{"issue":"1","key":"5739_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/01.tp.0000268524.27506.39","volume":"84","author":"CA Benavides","year":"2007","unstructured":"Benavides CA, Pollard VB, Mauiyyedi S et al (2007) BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes. Transplantation 84(1):83\u201388","journal-title":"Transplantation"},{"issue":"10","key":"5739_CR5","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.34067\/KID.0000000000000545","volume":"5","author":"M Bigotte Vieira","year":"2024","unstructured":"Bigotte Vieira M, Arai H, Nicolau C, Murakami N (2024) Cancer screening and cancer treatment in kidney transplant recipients. Kidney360 5(10):1569\u20131583","journal-title":"Kidney360"},{"issue":"9","key":"5739_CR6","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1111\/j.1600-6143.2005.01000.x","volume":"5","author":"DL Bohl","year":"2005","unstructured":"Bohl DL, Storch GA, Ryschkewitsch C et al (2005) Donor origin of BK virus in renal transplantation and role of HLA C7 in susceptibility to sustained BK viremia. Am J Transplant 5(9):2213\u20132221","journal-title":"Am J Transplant"},{"issue":"3","key":"5739_CR7","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/j.1600-6143.2005.00742.x","volume":"5","author":"DC Brennan","year":"2005","unstructured":"Brennan DC, Agha I, Bohl DL et al (2005) Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 5(3):582\u2013594","journal-title":"Am J Transplant"},{"issue":"3","key":"5739_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","volume":"41","author":"M Brunet","year":"2019","unstructured":"Brunet M, van Gelder T, \u00c5sberg A et al (2019) Therapeutic drug monitoring of tacrolimus\u2014personalized therapy: second consensus report. Ther Drug Monit 41(3):261\u2013307","journal-title":"Ther Drug Monit"},{"issue":"11","key":"5739_CR9","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1111\/j.1600-6143.2006.01540.x","volume":"6","author":"S Caillard","year":"2006","unstructured":"Caillard S, Lelong C, Pessione F, Moulin B (2006) Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry. Am J Transplant 6(11):2735\u20132742","journal-title":"Am J Transplant"},{"issue":"2","key":"5739_CR10","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1681\/ASN.2005090993","volume":"17","author":"JM Campistol","year":"2006","unstructured":"Campistol JM, Eris J, Oberbauer R et al (2006) Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 17(2):581\u2013589","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"5739_CR11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/imm.12162","volume":"140","author":"SP Cobbold","year":"2013","unstructured":"Cobbold SP (2013) The mTOR pathway and integrating immune regulation. Immunology 140(4):391\u2013398","journal-title":"Immunology"},{"issue":"13","key":"5739_CR12","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1056\/NEJMe058018","volume":"352","author":"J Dantal","year":"2005","unstructured":"Dantal J, Soulillou JP (2005) Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med 352(13):1371\u20131373","journal-title":"N Engl J Med"},{"issue":"1","key":"5739_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/FTD.0000000000000227","volume":"38","author":"MI de Paula","year":"2016","unstructured":"de Paula MI, Medina Pestana JO, Nicolau Ferreira A et al (2016) Long-term follow-up of de novo use of mTOR and calcineurin inhibitors after kidney transplantation. Ther Drug Monit 38(1):22\u201331","journal-title":"Ther Drug Monit"},{"issue":"10","key":"5739_CR14","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1097\/01.TP.0000123082.31092.53","volume":"77","author":"PG Dean","year":"2004","unstructured":"Dean PG, Lund WJ, Larson TS et al (2004) Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 77(10):1555\u20131561","journal-title":"Transplantation"},{"issue":"8","key":"5739_CR15","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.2215\/CJN.13221216","volume":"12","author":"AL Defined","year":"2017","unstructured":"Defined AL, El-Husseini A, Aull M et al (2017) CMV and BKPyV infections in renal transplant recipients receiving an mTOR inhibitor-based regimen versus a CNI-based regimen: a systematic review and meta-analysis of randomized, controlled trials. Clin J Am Soc Nephrol 12(8):1321\u20131336","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"5739_CR16","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1056\/NEJMra1702693","volume":"378","author":"D Dierickx","year":"2018","unstructured":"Dierickx D, Habermann TM (2018) Post-transplantation lymphoproliferative disorders in adults. N Engl J Med 378(6):549\u2013562","journal-title":"N Engl J Med"},{"issue":"6","key":"5739_CR17","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10(6):483\u2013486","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"5739_CR18","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B et al (2024) The REporting of A disproportionality analysis for drUg safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement. Drug Saf 47(6):575\u2013584","journal-title":"Drug Saf"},{"key":"5739_CR19","volume":"288","author":"K Goto","year":"2022","unstructured":"Goto K, Doi Y, Nishimura N et al (2022) The mTOR inhibitor everolimus attenuates tacrolimus-induced renal interstitial fibrosis in rats. Life Sci 288:120175","journal-title":"Life Sci"},{"issue":"Suppl 2","key":"5739_CR20","first-page":"21","volume":"21","author":"A Hart","year":"2019","unstructured":"Hart A, Lentine KL, Smith JM et al (2019) OPTN\/SRTR 2019 annual data report: kidney. Am J Transplant 21(Suppl 2):21\u2013137","journal-title":"Am J Transplant"},{"issue":"5","key":"5739_CR21","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SAW (2006) Under-reporting of adverse drug reactions: a systematic review. Drug Saf 29(5):385\u2013396","journal-title":"Drug Saf"},{"issue":"9","key":"5739_CR22","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1097\/TP.0000000000004976","volume":"108","author":"HH Hirsch","year":"2024","unstructured":"Hirsch HH, Babel N, Comoli P et al (2024) The second international consensus guidelines on the management of BK polyomavirus in kidney transplantation. Transplantation 108(9):1834\u20131857","journal-title":"Transplantation"},{"issue":"9","key":"5739_CR23","doi-asserted-by":"publisher","first-page":"e13528","DOI":"10.1111\/ctr.13528","volume":"33","author":"HH Hirsch","year":"2019","unstructured":"Hirsch HH, Randhawa PS (2019) AST infectious diseases community of practice. BK polyomavirus in solid organ transplantation\u2014guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 33(9):e13528","journal-title":"Clin Transplant"},{"issue":"10","key":"5739_CR24","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/nm.2497","volume":"17","author":"EJ Hoorn","year":"2011","unstructured":"Hoorn EJ, Walsh SB, McCormick JA et al (2011) The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. Nat Med 17(10):1304\u20131309","journal-title":"Nat Med"},{"issue":"7","key":"5739_CR25","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1681\/ASN.2007111202","volume":"19","author":"O Johnston","year":"2008","unstructured":"Johnston O, Rose CL, Webster AC, Gill JS (2008) Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 19(7):1411\u20131418","journal-title":"J Am Soc Nephrol"},{"key":"5739_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/1471-2369-14-207","volume":"14","author":"J Jacobi","year":"2013","unstructured":"Jacobi J, Prignitz A, B\u00fcttner M et al (2013) BK viremia and polyomavirus nephropathy in 352 kidney transplants; risk factors and potential role of mTOR inhibition. BMC Nephrol 14:207","journal-title":"BMC Nephrol"},{"issue":"7","key":"5739_CR27","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.3390\/jcm9072191","volume":"9","author":"MAM Khalil","year":"2020","unstructured":"Khalil MAM, Khalil MAU, Khan TFT, Tan J (2020) Drug-induced hematological cytopenia in kidney transplantation and the challenges it poses for kidney transplant physicians. J Clin Med 9(7):2191","journal-title":"J Clin Med"},{"key":"5739_CR28","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group (2009) KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 9(Suppl 3):S1\u2013S155","DOI":"10.1111\/j.1600-6143.2009.02834.x"},{"issue":"7","key":"5739_CR29","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1517\/14740338.2015.1040388","volume":"14","author":"J Klawitter","year":"2015","unstructured":"Klawitter J, Nashan B, Christians U (2015) Everolimus and sirolimus in transplantation-related but different. Expert Opin Drug Saf 14(7):1055\u20131070","journal-title":"Expert Opin Drug Saf"},{"key":"5739_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g6679","volume":"349","author":"GA Knoll","year":"2014","unstructured":"Knoll GA, Kokolo MB, Mallick R et al (2014) Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ 349:g6679","journal-title":"BMJ"},{"issue":"5","key":"5739_CR31","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1177\/0091270005275368","volume":"45","author":"JM Kovarik","year":"2005","unstructured":"Kovarik JM, Beyer D, Bizot MN et al (2005) Blood concentrations of everolimus are markedly increased by ketoconazole. J Clin Pharmacol 45(5):514\u2013518","journal-title":"J Clin Pharmacol"},{"key":"5739_CR32","doi-asserted-by":"publisher","unstructured":"Kumar A, Ahmad M, Hussain A et al (2025) Efficacy and safety of everolimus with reduced tacrolimus versus standard tacrolimus in liver transplant recipients: a systematic review and meta-analysis of randomized controlled trials. Transpl Immunol 93:102317. https:\/\/doi.org\/10.1016\/j.trim.2025.102317","DOI":"10.1016\/j.trim.2025.102317"},{"issue":"6","key":"5739_CR33","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1097\/00007890-200209270-00012","volume":"74","author":"RM Langer","year":"2002","unstructured":"Langer RM, Kahan BD (2002) Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients. Transplantation 74(6):804\u2013808","journal-title":"Transplantation"},{"issue":"2","key":"5739_CR34","doi-asserted-by":"publisher","first-page":"326","DOI":"10.2215\/CJN.03751106","volume":"2","author":"E Letavernier","year":"2007","unstructured":"Letavernier E, Bruneval P, Mandet C et al (2007) High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2(2):326\u2013333","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"5739_CR35","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.drudis.2015.05.006","volume":"20","author":"DJ Moes","year":"2015","unstructured":"Moes DJ, Guchelaar HJ, de Fijter JW (2015) Sirolimus and everolimus in kidney transplantation. Drug Discov Today 20(10):1243\u20131249","journal-title":"Drug Discov Today"},{"issue":"6","key":"5739_CR36","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"JL Montastruc","year":"2011","unstructured":"Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M (2011) Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol 72(6):905\u2013908","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"5739_CR37","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2215\/CJN.04800908","volume":"4","author":"M Naesens","year":"2009","unstructured":"Naesens M, Kuypers DRJ, Sarwal M (2009) Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 4(2):481\u2013508","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"5739_CR38","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1097\/TP.0000000000001243","volume":"100","author":"BJ Nankivell","year":"2016","unstructured":"Nankivell BJ, P\u2019Ng CH, O\u2019Connell PJ, Chapman JR (2016) Calcineurin inhibitor nephrotoxicity through the lens of longitudinal histology: comparison of cyclosporine and tacrolimus eras. Transplantation 100(8):1723\u20131731","journal-title":"Transplantation"},{"issue":"7","key":"5739_CR39","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s40264-019-00810-9","volume":"42","author":"LS Nguyen","year":"2019","unstructured":"Nguyen LS, Vautier M, Allenbach Y et al (2019) Sirolimus and mTOR inhibitors: a review of side effects and specific management in solid organ transplantation. Drug Saf 42(7):813\u2013825","journal-title":"Drug Saf"},{"issue":"4","key":"5739_CR40","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.trre.2013.06.001","volume":"27","author":"VR Peddi","year":"2013","unstructured":"Peddi VR, Wiseman A, Chavin K, Slakey D (2013) Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation. Transplant Rev 27(4):97\u2013107","journal-title":"Transplant Rev"},{"issue":"7","key":"5739_CR41","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1097\/TP.0b013e3181caeead","volume":"89","author":"H Pilmore","year":"2010","unstructured":"Pilmore H, Dent H, Chang S et al (2010) Reduction in cardiovascular death after kidney transplantation. Transplantation 89(7):851\u2013857","journal-title":"Transplantation"},{"issue":"2","key":"5739_CR42","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1586\/1744666X.2014.872562","volume":"10","author":"C Ponticelli","year":"2014","unstructured":"Ponticelli C (2014) The pros and the cons of mTOR inhibitors in kidney transplantation. Expert Rev Clin Immunol 10(2):295\u2013305","journal-title":"Expert Rev Clin Immunol"},{"key":"5739_CR43","first-page":"63","volume":"4","author":"K Ramasubbu","year":"2014","unstructured":"Ramasubbu K, Huang S, Fan Z et al (2014) Pharmacovigilance analysis of serious adverse events reported for biologic response modifiers used as prophylaxis against transplant rejection: a real-world postmarketing experience from the US FDA Adverse Event Reporting System (FAERS). Biosimilars 4:63\u201371","journal-title":"Biosimilars"},{"issue":"8","key":"5739_CR44","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST (2004) The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 13(8):519\u2013523","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"5739_CR45","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y (2013) Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci 10(7):796\u2013803","journal-title":"Int J Med Sci"},{"issue":"6","key":"5739_CR46","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/j.1399-3062.2011.00649.x","volume":"13","author":"AI Sanchez Fructuoso","year":"2011","unstructured":"Sanchez Fructuoso AI, Calvo N, Perez-Flores I et al (2011) Mammalian target of rapamycin signal inhibitors could play a role in the treatment of BK polyomavirus nephritis in renal allograft recipients. Transpl Infect Dis 13(6):584\u2013591","journal-title":"Transpl Infect Dis"},{"issue":"2","key":"5739_CR47","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/ndt\/gfu023","volume":"30","author":"D Sawinski","year":"2015","unstructured":"Sawinski D, Goral S (2015) BK virus infection: an update on diagnosis and treatment. Nephrol Dial Transplant 30(2):209\u2013217","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"5739_CR48","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/TP.0b013e3181927a41","volume":"87","author":"FP Schena","year":"2009","unstructured":"Schena FP, Pascoe MD, Alberu J et al (2009) Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplant 87(2):233\u2013242","journal-title":"Transplant"},{"issue":"1","key":"5739_CR49","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/00007890-199707150-00008","volume":"64","author":"W Schuler","year":"1997","unstructured":"Schuler W, Sedrani R, Cottens S et al (1997) SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 64(1):36\u201342","journal-title":"Transplantation"},{"issue":"3","key":"5739_CR50","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1681\/ASN.2008060591","volume":"20","author":"DL Segev","year":"2009","unstructured":"Segev DL, Kucirka LM, Oberai PC et al (2009) Age and comorbidities are effect modifiers of gender disparities in renal transplantation. J Am Soc Nephrol 20(3):621\u2013628","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"5739_CR51","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1432-2277.2008.00780.x","volume":"22","author":"M Senzolo","year":"2009","unstructured":"Senzolo M, Ferronato C, Burra P (2009) Neurologic complications after solid organ transplantation. Transpl Int 22(3):269\u2013278","journal-title":"Transpl Int"},{"issue":"1","key":"5739_CR52","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1210\/er.2015-1084","volume":"37","author":"V Shivaswamy","year":"2016","unstructured":"Shivaswamy V, Boerner B, Larsen J (2016) Post-transplant diabetes mellitus: causes, treatment, and impact on outcomes. Endocr Rev 37(1):37\u201361","journal-title":"Endocr Rev"},{"issue":"6","key":"5739_CR53","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","volume":"25","author":"A Szarfman","year":"2002","unstructured":"Szarfman A, Machado SG, O\u2019Neill RT (2002) Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database. Drug Saf 25(6):381\u2013392","journal-title":"Drug Saf"},{"issue":"1","key":"5739_CR54","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/TP.0000000000004749","volume":"108","author":"J Toniato de Rezende Freschi","year":"2024","unstructured":"Toniato de Rezende Freschi J et al (2024) A head-to-head comparison of de novo sirolimus or everolimus plus reduced-dose tacrolimus in kidney transplant recipients: a prospective and randomized trial. Transplantation 108(1):261\u2013275","journal-title":"Transplantation"},{"issue":"7","key":"5739_CR55","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.bcp.2008.12.009","volume":"77","author":"HH van Rossum","year":"2009","unstructured":"van Rossum HH, Romijn FP, Smit NP, de Fijter JW, van Pelt J (2009) Everolimus and sirolimus antagonize tacrolimus based calcineurin inhibition via competition for FK-binding protein 12. Biochem Pharmacol 77(7):1206\u20131212","journal-title":"Biochem Pharmacol"},{"key":"5739_CR56","unstructured":"World Health Organization. Global observatory on donation and transplantation. Available at: \nhttp:\/\/www.transplant-observatory.org. Accessed 2025"},{"issue":"4","key":"5739_CR57","volume":"18","author":"S Yin","year":"2023","unstructured":"Yin S, Song T, Jiang Y et al (2023) The incidence of cytomegalovirus and BK polyomavirus infections in kidney transplant patients receiving mTOR inhibitors: a systematic review and meta-analysis. PLoS ONE 18(4):e0284117","journal-title":"PLoS ONE"},{"issue":"3","key":"5739_CR58","doi-asserted-by":"publisher","DOI":"10.2196\/19266","volume":"6","author":"Z Zhou","year":"2020","unstructured":"Zhou Z, Hultgren KE (2020) Complementing the US Food and Drug Administration adverse event reporting system with adverse drug reaction reporting from social media: comparative analysis. JMIR Public Health Surveill 6(3):e19266","journal-title":"JMIR Public Health Surveill"},{"key":"5739_CR59","doi-asserted-by":"publisher","first-page":"1338902","DOI":"10.3389\/fphar.2024.1338902","volume":"15","author":"F Zou","year":"2024","unstructured":"Zou F, Cui Z, Lou S et al (2024) Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database. Front Pharmacol 15:1338902","journal-title":"Front Pharmacol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05739-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05739-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05739-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:01:52Z","timestamp":1792886512000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05739-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":59,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["5739"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05739-2","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"16 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study used publicly available, anonymized data from the FDA FAERS database. Ethical approval and informed consent were not required.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}